Hospice management of patients receiving cytotoxic chemotherapy: problems and opportunities.
In Britain, the specialty of palliative medicine continues to develop, encouraging the referral of patients early in the palliative phase of their illness. This had led to an increased number of patients receiving palliative chemotherapy and hospice care concurrently, posing special problems to the professionals involved. In this retrospective study, 52 patients were identified who received chemotherapy and hospice care simultaneously. Case notes were reviewed to reveal problems arising from sharing the duty of care. The poor quality of communication between professionals, perhaps reflecting a limited understanding of the various roles in patient care, we found to cause significant difficulties. The duration and discontinuation of cytotoxic therapy seems to be a particularly difficult matter. Hospice admission often signalled the end of this treatment. In a third of the patients, no decision was taken to stop chemotherapy despite the last dose being an average of just 1 week before death. The value of chemotherapy for patients who are too ill to return home is questioned. Seven patients were diagnosed as suffering from chemotherapy-induced sepsis and neutropenia either by hospice inpatient or home care teams, and were admitted to their acute centres accordingly. Most patients who died during the study period received terminal care in the hospice. Suggestions are made on improving professional education and communication, including the use of a 'chemotherapy card'.
Hicks
F
F
St Gemma's Hospice, Moortown, Leeds, UK.
Corcoran
G
G
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003142:Communication; D004358:Drug Therapy / Q000706:statistics & numerical data*; D005260:Female; D017051:Hospice Care / Q000458:organization & administration*; D006801:Humans; D007400:Interprofessional Relations; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D012189:Retrospective Studies; D006113:United Kingdom
D000970:Antineoplastic Agents